Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation